JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Icahn School of Medicine at Mount Sinai
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (8)
2022
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2021
-
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Journal of Clinical Pharmacology, Vol. 61, Núm. 5, pp. 614-627
-
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Haematologica, Vol. 106, Núm. 6, pp. 1725-1732
-
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
The Lancet, Vol. 398, Núm. 10301, pp. 665-674
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2019
-
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 8, pp. 668-677
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051